ABSTRACT
PURPOSE: To compare Thais' health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. DESIGN: Prospective-observational study. PARTICIPANTS: BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. METHODS: Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. RESULTS: 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. CONCLUSION: Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.
Subject(s)
Blepharospasm , Botulinum Toxins, Type A , Humans , Female , Middle Aged , Aged , Male , Quality of Life , Prospective Studies , Blepharospasm/drug therapy , Surveys and Questionnaires , Health StatusABSTRACT
Purpose: To demonstrate the association between SARS-CoV-2 infection and MOG antibody associated optic neuritis. Observations: A 35-year-old Thai woman presented with acute blurred vision of her left eye with pain on eye movement for six days and had dry cough for one week before the onset of visual loss. Her visual acuity was 20/32 in the right eye and counting fingers with a RAPD in the left eye. She had bilateral disc swelling, more prominent on the left eye. A CT scan of the brain and orbits showed swollen optic nerve sheath complex both eyes. Serology test was positive for serum anti-myelin oligodendrocyte glycoprotein (MOG) antibody. Her nasopharyngeal swab for SARS-CoV-2 PCR was also positive. The diagnosis of SARS-CoV-2 associated MOG antibody optic neuritis was made. Conclusions and importance: This case of MOG antibody associated optic neuritis after COVID-19 infection, along with several other cases reported in the literature, suggests that there may be an association between COVID-19 infection and MOG antibody-associated disease. However, larger case-controlled studies are required to confirm this association.
ABSTRACT
PURPOSE: The purpose of this study was to compare ocular complications and efficacy of preseptal (PST) versus those of pretarsal (PTS) botulinum toxin type A (BoNT-A) therapy in cases of benign essential blepharospasm (BEB). DESIGN: Randomized clinical trial. METHODS: Setting: university hospital. PATIENTS: 24 participants with BEB were enrolled from August 2019 to June 2020. All patients and the outcome evaluator were masked to the injection allocation. INTERVENTIONS: for each participant, 1 eye was randomized to receive PST BoNT-A injection, and the fellow eye received PTS BoNT-A injection of the same amount from a single investigator. At baseline, 1, and 3 months after the injection, we collected the symptoms of tearing, lagophthalmos, ptosis, and diplopia and measured margin-to-reflex distance (MRD) 1 and 2 (mm), degree of lagophthalmos (mm), presence of ectropion, entropion, limitation of ocular motility, tear film breakup time (second), Schirmer's test (mm) , ocular surface staining scores (Oxford's scheme), and Jankovic rating scale of both eyes separately. Main outcome measurements were complications of the injection. RESULTS: There were statistically significant higher rates of self-reported lagophthalmos in PTS (n = 12; 52.17%) than in PST (n = 7; 30.43%) BoNT-A injections (P = .024) and significantly higher estimated measurements of lagophthalmos in PTS (0.59 mm; 95% confidence interval [CI]: 0.44-0.72) than in PST (0.26 mm; 95% CI: 0.12-0.40) injection at 1 month using an interaction model (Bonferroni-corrected P = .001). No significant differences in the efficacy and other complication outcomes between the injection locations were observed. CONCLUSIONS: PTS BoNT-A injection had a higher rate of lagophthalmos than PST BoNT-A injection for BEB.